News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Sullivan Lara
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/04/2023 |
SC 13D/A
| Sullivan Lara reports a 10.2% stake in Pyxis Oncology, Inc. |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2023 |
4
| Sullivan Lara (CEO) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 95,684 shares
@ $0 |
|
| 05/23/2022 |
SC 13D/A
| Sullivan Lara reports a 9.6% stake in Pyxis Oncology, Inc. |
| 04/15/2022 |
4
| Sullivan Lara (CEO) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 315,273 shares
@ $0 |
|
| 04/04/2022 |
4
| Sullivan Lara (CEO) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 742,574 shares
@ $0 |
|
| 10/12/2021 |
4
| Sullivan Lara (CEO) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 962,289 options to buy
@ $16, valued at
$15.4M
|
|
| 10/07/2021 |
3
| Sullivan Lara (CEO) has filed a Form 3 on Pyxis Oncology, Inc. |
| 06/07/2019 |
4
| Sullivan Lara (Director) has filed a Form 4 on REXAHN PHARMACEUTICALS, INC.|
Txns:
| Granted 3,537 options to buy
@ $5.23, valued at
$18.5k
|
|
| 03/01/2019 |
4
| Sullivan Lara (Director) has filed a Form 4 on REXAHN PHARMACEUTICALS, INC.|
Txns:
| Granted 84,968 options to buy
@ $0.53, valued at
$45k
|
|
| 03/01/2019 |
3
| Sullivan Lara (Director) has filed a Form 3 on REXAHN PHARMACEUTICALS, INC. |
|
|